Differences in Due Process during Post-Conviction: Examining Jurisdictional Influence on Exoneration

Research on wrongful conviction has found several factors associated with an erroneous conviction. As of yet, research has not delved into the jurisdictional effects on exoneration. Using the American State’s use of the death penalty for a proxy of punitiveness, this study will examine if there is a relationship between use of capital punishment and exoneration rates. The National Registry of Exonerations is the most comprehensive collection of exonerations to date and this secondary data source will be analyzed using logistic regression models to examine differences across policy environments. Result show that non-death penalty states have a much higher exoneration rate, with significant gender and race patterns showing greater exoneration of Blacks and female defendants in death penalty states

Differences in Due Process during Post-Conviction: Examining Jurisdictional Influence on Exoneration

Research on wrongful conviction has found several factors associated with an erroneous conviction. As of yet, research has not delved into the jurisdictional effects on exoneration. Using the American State’s use of the death penalty for a proxy of punitiveness, this study will examine if there is a relationship between use of capital punishment and exoneration rates. The National Registry of Exonerations is the most comprehensive collection of exonerations to date and this secondary data source will be analyzed using logistic regression models to examine differences across policy environments. Result show that non-death penalty states have a much higher exoneration rate, with significant gender and race patterns showing greater exoneration of Blacks and female defendants in death penalty states

Thinking and Reading Among College Undergraduates: An Examination of the Relationship between Critical Thinking Skills and Voluntary Reading

Many scholars have weighed in on what it means to think critically. Although there has not been agreement on a clear definition for the term “critical thinking,” scholars have agreed on some common skills involved in critical thinking. These skills—inductive reasoning, deductive reasoning, analysis, evaluation, and inference are the same ones involved in the ability to read and read well. While many studies have involved critical thinking in college students, none has examined critical thinking and its relationship to reading. Thus, the purpose of this study was to determine the relationship between voluntary reading, academic achievement (as measured by GPA), and critical thinking skills among undergraduate students. A quantitative research design involved 119 students at a private, denominationally-affiliated liberal arts college in the South. Students in seven sections of undergraduate English completed the Survey of Recreational Reading Habits, Revised as well as the California Critical Thinking Skills Test (CCTST). Critical thinking was operationally defined by the total score on the CCTST, and it was studied more closely by examining scores on its five sub-scales. Voluntary reading involved four variables: 1) the number of hours spent per week on voluntary reading while college classes are in session, 2) the number of hours spent per week on voluntary reading during vacation breaks from college, 3) the frequency of reading books, and 4) the frequency of reading non-book items. Statistical analyses yielded the following results: 1) there was a significant, positive relationship between critical thinking and voluntary reading; 2) gender and class standing did not make a significant difference in critical thinking score; 3) there was a significant, positive relationship between college GPA and each score on the CCTST (total score and all five sub-scores); and 4) there was a significant, positive relationship between voluntary reading and college GPA

Overcoming Innocents’ Naiveté: Pre‐interrogation Decision‐making Among Innocent Suspects

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/133623/1/bsl2247.pd

Policy Recommendations for Meeting the Grand Challenge to Ensure Healthy Development for All Youth

This brief was created forSocial Innovation for America’s Renewal, a policy conference organized by the Center for Social Development in collaboration with the American Academy of Social Work & Social Welfare, which is leading theGrand Challenges for Social Work initiative to champion social progress. The conference site includes links to speeches, presentations, and a full list of the policy briefs

Loss of heterozygosity and SOSTDC1 in adult and pediatric renal tumors

<p>Abstract</p> <p>Background</p> <p>Deletions within the short arm of chromosome 7 are observed in approximately 25% of adult and 10% of Wilms pediatric renal tumors. Within Wilms tumors, the region of interest has been delineated to a 2-Mb minimal region that includes ten known genes. Two of these ten candidate genes, <it>SOSTDC1 </it>and <it>MEOX2</it>, are particularly relevant to tumor development and maintenance. This finding, coupled with evidence that SOSTDC1 is frequently downregulated in adult renal cancer and regulates both Wingless-Int (Wnt)- and bone morphogenetic protein (BMP)-induced signaling, points to a role for SOSTDC1 as a potential tumor suppressor.</p> <p>Methods</p> <p>To investigate this hypothesis, we interrogated the Oncomine database to examine the SOSTDC1 levels in adult renal clear cell tumors and pediatric Wilms tumors. We then performed single nucleotide polymorphism (SNP) and sequencing analyses of <it>SOSTDC1 </it>in 25 pediatric and 36 adult renal tumors. Immunohistochemical staining of patient samples was utilized to examine the impact of <it>SOSTDC1 </it>genetic aberrations on SOSTDC1 protein levels and signaling.</p> <p>Results</p> <p>Within the Oncomine database, we found that SOSTDC1 levels were reduced in adult renal clear cell tumors and pediatric Wilms tumors. Through SNP and sequencing analyses of 25 Wilms tumors, we identified four with loss of heterozygosity (LOH) at 7p and three that affected <it>SOSTDC1</it>. Of 36 adult renal cancers, we found five with LOH at 7p, two of which affected <it>SOSTDC1</it>. Immunohistochemical analysis of SOSTDC1 protein levels within these tumors did not reveal a relationship between these instances of <it>SOSTDC1 </it>LOH and SOSTDC1 protein levels. Moreover, we could not discern any impact of these genetic alterations on Wnt signaling as measured by altered beta-catenin levels or localization.</p> <p>Conclusions</p> <p>This study shows that genetic aberrations near <it>SOSTDC1 </it>are not uncommon in renal cancer, and occur in adult as well as pediatric renal tumors. These observations of <it>SOSTDC1 </it>LOH, however, did not correspond with changes in SOSTDC1 protein levels or signaling regulation. Although our conclusions are limited by sample size, we suggest that an alternative mechanism such as epigenetic silencing of <it>SOSTDC1 </it>may be a key contributor to the reduced SOSTDC1 mRNA and protein levels observed in renal cancer.</p

A cross-sectional survey on the early impact of COVID-19 on the uptake of decentralised trial methods in the conduct of clinical trials

BACKGROUND: The COVID-19 pandemic significantly impacted the conduct of clinical trials through delay, interruption or cancellation. Decentralised methods in clinical trials could help to continue trials during a pandemic. This paper presents the results of an exploratory study conducted early in the pandemic to gain insight into and describe the experiences of organisations involved in clinical trials, with regard to the impact of COVID-19 on the conduct of trials, and the adoption of decentralised methods prior to, and as mitigation for the impact, of COVID-19. METHODS: A survey with 11 open-ended and four multiple choice questions was conducted in June 2020 among member organisations of the public-private “Trials@Home” consortium. The survey investigated (1) the impact and challenges of COVID-19 on the continuation of ongoing clinical trials, (2) the adoption of decentralised methods in clinical trials prior to and as a mitigation strategy for COVID-19, (3) the challenges of conducting clinical trials during COVID-19, (4) the expected permanency of COVID-19-driven changes to the adoption of decentralised methods in clinical trials, and (5) lessons learned from conducting clinical trials during the COVID-19 pandemic. A thematic, inductive analysis of open survey questions was performed, complemented with descriptive statistics (frequencies and distributions). RESULTS: The survey had a response rate of 81%. All organisations included in the analysis (n = 18) implemented (some) decentralised methods in their clinical trials prior to COVID-19, and 15 (83%) implemented decentralised methods as mitigation for COVID-19. Decentralised methods for IMP supply, patient-health care provider interaction and communication, clinic visits and source document verification were used more often as mitigation strategies than they were used prior to COVID-19. Many respondents expect to maintain those decentralised methods they implemented during COVID-19 in ongoing trials, as well as implement them in future trials. CONCLUSIONS: Decentralised methods are a widely implemented mitigation strategy for trial conduct in the face of the COVID-19 pandemic. The results of this survey show that there is an interest to continue the use of decentralised methods in future trials, but important points of attention have been identified that need solutions to help guide the transition from the traditional trial model to a more decentralised trial model. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-022-06706-x

EZH2 Cooperates with BRD4-NUT to Drive NUT Carcinoma Growth by Silencing Key Tumor Suppressor Genes

NUT carcinoma (NC) is an aggressive carcinoma driven by the BRD4-NUT fusion oncoprotein, which activates chromatin to promote expression of pro-growth genes. BET bromodomain inhibitors (BETi) are a promising treatment for NC that can impede BRD4-NUT’s ability to activate genes, but the efficacy of BETi as monotherapy are limited. Here, we demonstrated that EZH2, which silences genes through establishment of repressive chromatin, is a dependency in NC. Inhibition of EZH2 with the clinical compound tazemetostat (taz) potently blocked growth of NC cells. Epigenetic and transcriptomic analysis revealed that taz reversed the EZH2-specific H3K27me3 silencing mark and restored expression of multiple tumor suppressor genes while having no effect on key oncogenic BRD4-NUT-regulated genes. Indeed, H3K27me3 and H3K27ac domains were found to be mutually exclusive in NC cells. CDKN2A was identified as the only gene among all taz-derepressed genes to confer resistance to taz in a CRISPR-Cas9 screen. Combined inhibition of EZH2 and BET synergized to downregulate cell proliferation genes resulting in more pronounced growth arrest and differentiation than either inhibitor alone. In pre-clinical models, combined taz and BETi synergistically blocked tumor growth and prolonged survival of NC-xenografted mice, with complete remission without relapse in one cohort. Identification of EZH2 as a dependency in NC substantiates the reliance of NC tumor cells on epigenetic dysregulation of functionally opposite, yet highly complementary, chromatin regulatory pathways to maintain NC growth